A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

Annals of Surgical Oncology

Volumn 21, Issue 12, 2014, Pages 4041-4048

  Tanaka, Nobuyuki ^a,h   Kikuchi, Eiji ^a   Kanao, Kent ^a   Matsumoto, Kazuhiro ^a,b   Shirotake, Suguru ^a,c   Miyazaki, Yasumasa ^a,j   Kobayashi, Hiroaki ^a,f   Kaneko, Gou ^a,g   Hagiwara, Masayuki ^a,i   Ide, Hiroki ^a,k   Obata, Jun ^a   Hoshino, Katsura ^a   Hayakawa, Nozomi ^a,b   Kosaka, Takeo ^a,l   Hara, Satoshi ^g   Oyama, Masafumi ^c   Momma, Tetsuo ^d   Nakajima, Yosuke ^e   Jinzaki, Masahiro ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d SAITAMA NATIONAL HOSPITAL   (Japan)

^e SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^f Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^g Department of Urology Kawasaki City Hospital   (Japan)

^h Musashino Hospital   (Japan)

ⁱ TOKYO DENTAL COLLEGE   (Japan)

^j Ogikubo Hospital   (Japan)

^k Inagi City Hospital   (Japan)

^l Irumagawa Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; NEUTROPHIL LYMPHOCYTE RATIO; PREOPERATIVE EVALUATION; RADICAL NEPHROURETERECTOMY; RECURRENCE FREE SURVIVAL; RISK FACTOR; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; LYMPHOCYTE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR INVASION; URETER; UROLOGIC NEOPLASMS; VALIDATION STUDY;

TUMOR MARKER;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URETER; UROLOGIC NEOPLASMS;

EID: 84918786598     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3830-3     Document Type: Article

References (30)

1. Roupret M, Babjuk M, Comperat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63:1059–1071.
2. Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62:100–114.
3. Rink M, Sjoberg D, Comploj E, et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol. 2012;19:4337–4344.
4. Tanaka N, Kikuchi E, Kanao K, et al. Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol. 2013;21:1038–45.
5. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224–1233.
6. Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61:818–825.
7. Ouzzane A, Colin P, Xylinas E, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol. 2011;60:1258–1265.
8. Yates DR, Hupertan V, Colin P, et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer. 2012;106:1083–1088.
9. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359–1370.
10. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–322.
11. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012;13:343–351.
12. Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–421.
13. de Martino M, Pantuck AJ, Hofbauer S, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013;190:1999–2004.
14. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107:695–699.
15. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108:901–907.
16. Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19:217–224.
17. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 2012;79:1085–1091.
18. Can C, Baseskioglu B, Yilmaz M, et al. Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol Int. 2012;89:468–472.
19. Luo HL, Chen YT, Chuang YC, et al. Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. BJU Int. 2014;113:E144–149.
20. Hashimoto T, Ohno Y, Nakashima J, et al. Clinical significance of preoperative peripheral blood neutrophil count in patients with non-metastatic upper urinary tract carcinoma. World J Urol. 2013;31:953–958.
21. Krane LS, Richards KA, Kader AK, et al. Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol 2013;27:1046–1050.
22. Dalpiaz O, Ehrlich GC, Mannweiler S, et al. Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int. 2013. doi: 10.1111/bju.12441.
23. Azuma T, Matayoshi Y, Odani K, et al. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer. 2013;11:337–341.
24. Rink M, Fajkovic H, Cha EK, et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol. 2012;61:854–855.
25. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387.
26. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10:4895–4900.
27. Gakis G, Todenhofer T, Renninger M, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011;108:1800–1805.
28. Tanaka N, Kikuchi E, Matsumoto K, et al. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma. BJU Int. 2013;111:857–864.
29. Andrews B, Shariat SF, Kim JH, et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002;167:1475–1481.
30. Dalpiaz O, Pichler M, Mannweiler S, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer. 2014;110(10):2531–2536.